FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA® (tocilizumab)GlobeNewsWire • 12/09/22
Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum DepressionBusiness Wire • 12/06/22
European Medicines Agency Accepts Tofersen Marketing Authorization Application to Treat Rare, Genetic Form of ALSGlobeNewsWire • 12/05/22
Biogen Inc. (BIIB) 5th Annual Evercore ISI HealthCONx Conference 2022 - (Transcript)Seeking Alpha • 12/02/22
5 things to know about the new Alzheimer's drug — including why it may be risky for people who take blood thinnersMarket Watch • 11/30/22
Biogen stock up 3% premarket after update on Alzheimer's treatment; Stifel reiterates buy ratingMarket Watch • 11/30/22
Why This New Alzheimer's Update Is Likely To Spark A Debate For Biogen InvestorsInvestors Business Daily • 11/30/22
New Alzheimer's drug slows decline in memory - fuelling hope doctors will one day cure dementiaSkynews • 11/30/22
Eisai, Biogen Alzheimer's drug slows cognitive decline, safety for some becomes focusReuters • 11/30/22
ELEVEN EXPERTS FROM LEADING MEDICAL INSTITUTIONS AND EIGHT EXPERTS FROM EISAI* PUBLISH FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE IN THE NEW ENGLAND JOURNAL OF MEDICINEPRNewsWire • 11/30/22
EISAI PRESENTS FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE AT CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCEPRNewsWire • 11/30/22